NZ628882A - Use of ccr3-inhibitors - Google Patents

Use of ccr3-inhibitors

Info

Publication number
NZ628882A
NZ628882A NZ628882A NZ62888213A NZ628882A NZ 628882 A NZ628882 A NZ 628882A NZ 628882 A NZ628882 A NZ 628882A NZ 62888213 A NZ62888213 A NZ 62888213A NZ 628882 A NZ628882 A NZ 628882A
Authority
NZ
New Zealand
Prior art keywords
eosinophilic
alkyl
macular degeneration
related macular
syndrome
Prior art date
Application number
NZ628882A
Other languages
English (en)
Inventor
Michael Chadham Nivens
Thierry Bouyssou
Rolf Goeggel
Peter Seither
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48040249&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ628882(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of NZ628882A publication Critical patent/NZ628882A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Immunology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Structure Of Transmissions (AREA)
NZ628882A 2012-04-03 2013-04-02 Use of ccr3-inhibitors NZ628882A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12162937 2012-04-03
PCT/EP2013/056864 WO2013149986A1 (en) 2012-04-03 2013-04-02 Use of ccr3-inhibitors

Publications (1)

Publication Number Publication Date
NZ628882A true NZ628882A (en) 2016-05-27

Family

ID=48040249

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ628882A NZ628882A (en) 2012-04-03 2013-04-02 Use of ccr3-inhibitors

Country Status (28)

Country Link
US (5) US20130261153A1 (OSRAM)
EP (3) EP2833884B1 (OSRAM)
JP (2) JP2015512432A (OSRAM)
KR (5) KR20200044988A (OSRAM)
CN (2) CN110384699A (OSRAM)
AU (1) AU2013245027B2 (OSRAM)
BR (1) BR112014023795B1 (OSRAM)
CA (1) CA2869269C (OSRAM)
CL (1) CL2014002523A1 (OSRAM)
CY (1) CY1123222T1 (OSRAM)
DK (1) DK2833884T3 (OSRAM)
EA (1) EA032263B1 (OSRAM)
ES (2) ES2811554T3 (OSRAM)
HR (1) HRP20201165T1 (OSRAM)
HU (1) HUE051648T2 (OSRAM)
IL (1) IL234262A (OSRAM)
IN (1) IN2014DN06989A (OSRAM)
LT (1) LT2833884T (OSRAM)
MX (1) MX2014011786A (OSRAM)
NZ (1) NZ628882A (OSRAM)
PH (1) PH12014502239A1 (OSRAM)
PL (1) PL2833884T3 (OSRAM)
PT (1) PT2833884T (OSRAM)
RS (1) RS60665B1 (OSRAM)
SI (1) SI2833884T1 (OSRAM)
SM (1) SMT202000499T1 (OSRAM)
WO (1) WO2013149986A1 (OSRAM)
ZA (1) ZA201406082B (OSRAM)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8278302B2 (en) 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
UA109290C2 (uk) 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
US8680280B2 (en) 2012-04-02 2014-03-25 Boehringer Ingelheim International Gmbh Process for the manufacturing of CRR inhibitors
US20130261153A1 (en) * 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10213421B2 (en) 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
WO2018097209A1 (ja) 2016-11-24 2018-05-31 キリシマ精工株式会社 歯列矯正具、および歯列矯正具の取付方法
BR112019020798A2 (pt) * 2017-04-05 2020-04-28 Alkahest Inc métodos e composições para tratamento de danos associados ao envelhecimento usando inibidores de ccr3
JP7179755B2 (ja) * 2017-04-05 2022-11-29 アルカヘスト インコーポレイテッド Ｃｃｒ３阻害剤を使用した網膜関連疾患を治療するための方法および組成物
KR20200067859A (ko) * 2017-10-13 2020-06-12 알카헤스트 인코포레이티드 Ccr3-억제제를 사용한 소양증, 건조증, 및 관련 질환을 치료하기 위한 방법 및 조성물
US11426399B2 (en) 2018-05-15 2022-08-30 Alkahest, Inc. Treatment of aging-associated disease with modulators of leukotriene A4 hydrolase
WO2020069008A1 (en) * 2018-09-26 2020-04-02 Alkahest, Inc. Methods and compositions for treating aging-associated impairments using ccr3-inhibitors
AU2021287906B2 (en) * 2020-06-11 2025-09-11 Alkahest Inc. Methods of improving retina-associated disease outcome using CCR3-inhibitors
US11957671B2 (en) 2021-11-01 2024-04-16 Alkahest, Inc. Benzodioxane modulators of leukotriene A4 hydrolase (LTA4H) for prevention and treatment of aging-associated diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6339087B1 (en) * 1997-08-18 2002-01-15 Syntex (U.S.A.) Llc Cyclic amine derivatives-CCR-3 receptor antagonists
JP5198704B2 (ja) * 2000-03-03 2013-05-15 メディミューン リミティド エオタキシンに対するヒト抗体及びそれらの使用
US20020151064A1 (en) * 2001-02-07 2002-10-17 Children's Hospital Medical Center Regulation of CCR3 expression
US8030003B2 (en) * 2004-12-07 2011-10-04 Children's Hospital Medical Center Diagnosis of eosinophilic esophagitis based on presence of an elevated level of eotaxin-3
US8008092B2 (en) * 2007-10-09 2011-08-30 University Of Kentucky Research Foundation CCR3 inhibition for ocular angiogenesis and macular degeneration
WO2010069979A1 (en) * 2008-12-16 2010-06-24 Nycomed Gmbh Pyran derivatives as ccr3 modulators
EP2236520A1 (en) * 2009-03-31 2010-10-06 Leukocare Ag Stabilizing composition for immobilized biomolecules
US8278302B2 (en) * 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
US8778616B2 (en) * 2009-05-26 2014-07-15 University Of Kentucky Research Foundation Method of using CCR3 binding agents to detect choroidal neovascularization
UA109290C2 (uk) * 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
US20130261153A1 (en) * 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10213421B2 (en) * 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
WO2020115836A1 (ja) * 2018-12-05 2020-06-11 東浜工業株式会社 ブロワー装置

Also Published As

Publication number Publication date
PL2833884T3 (pl) 2020-11-02
JP2018080183A (ja) 2018-05-24
RS60665B1 (sr) 2020-09-30
ZA201406082B (en) 2019-01-30
KR20220132012A (ko) 2022-09-29
IN2014DN06989A (OSRAM) 2015-04-10
US20150099783A1 (en) 2015-04-09
EP2833884B1 (en) 2020-05-20
AU2013245027A1 (en) 2014-09-11
PH12014502239A1 (en) 2014-12-15
US20130261153A1 (en) 2013-10-03
EA032263B1 (ru) 2019-05-31
EP3763369B1 (en) 2024-02-28
BR112014023795A2 (OSRAM) 2017-06-20
EP3763369A1 (en) 2021-01-13
EP4389217A2 (en) 2024-06-26
KR20210063481A (ko) 2021-06-01
JP2015512432A (ja) 2015-04-27
BR112014023795A8 (pt) 2017-10-10
EP4389217A3 (en) 2024-08-28
PT2833884T (pt) 2020-08-26
HRP20201165T1 (hr) 2020-12-11
HUE051648T2 (hu) 2021-03-29
US20160081998A1 (en) 2016-03-24
IL234262A (en) 2017-10-31
KR20200044988A (ko) 2020-04-29
LT2833884T (lt) 2020-09-10
CY1123222T1 (el) 2021-10-29
SMT202000499T1 (it) 2020-11-10
US20200375971A1 (en) 2020-12-03
BR112014023795B1 (pt) 2021-09-08
CN104220073A (zh) 2014-12-17
KR20140144200A (ko) 2014-12-18
ES2811554T3 (es) 2021-03-12
CN110384699A (zh) 2019-10-29
EP2833884A1 (en) 2015-02-11
DK2833884T3 (da) 2020-08-10
CL2014002523A1 (es) 2015-01-23
MX2014011786A (es) 2014-12-05
KR20250133980A (ko) 2025-09-09
SI2833884T1 (sl) 2020-10-30
EA201401083A1 (ru) 2015-03-31
US20170319567A1 (en) 2017-11-09
WO2013149986A1 (en) 2013-10-10
CA2869269C (en) 2020-06-30
ES2987267T3 (es) 2024-11-14
AU2013245027B2 (en) 2017-10-12
CA2869269A1 (en) 2013-10-10

Similar Documents

Publication Publication Date Title
NZ628882A (en) Use of ccr3-inhibitors
EA201391486A1 (ru) Способы и композиции для лечения болезни паркинсона
SA518400493B1 (ar) مركبات كارفيلزوميب معالجة ببولي إيثيلين جليكول
MD4800B1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
PH12019500480A1 (en) Pyridine compound
EA201590930A1 (ru) Лекарственные формы руксолитиниба с замедленным высвобождением
JO3453B1 (ar) مشتقات البنزاميد لتثبيط نشاط abl1 و abl2 و bcr-abl1
EA201591753A1 (ru) 3-пиримидин-4-илоксазолидин-2-оны в качестве ингибиторов мутантного idh
NZ703989A (en) Alkoxy pyrazoles as soluble guanylate cyclase activators
WO2012142093A3 (en) 2'-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
NZ703064A (en) Inhibitors of hepatitis c virus
EA201100138A1 (ru) 4-феноксиметилпиперидины в качестве модуляторов активности gpr119
MD20150075A2 (ro) Compuşi tetraciclici heterociclu-substituiţi şi metode de utilizare a acestora pentru tratamentul bolilor virale
MX2013014007A (es) [1,3] oxazinas.
MX2014014106A (es) Derivados de acido 7-oxo-tiazolopiridinocarbonico y su uso en el tratamiento, disminucion o prevencion de una enfermedad viral.
GEP20156318B (en) Heteroaryl derivatives as alpha7 nachr modulators
PH12013500644A1 (en) Co-crystals and salts of ccr3-inhibitors
MX2015008288A (es) Derivados de piridona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral.
PH12014502541A1 (en) 5-amino [1,4] thiazines as bace 1 inhibitors
BR112014000499A2 (pt) compostos de quinolona de aminometila
MX370010B (es) Inhibidores de tirosina cinasa de bruton.
MX380758B (es) Compuesto que tiene actividad inhibitoria de idh mutante, método de preparación y usos del mismo.
MX374759B (es) Inhibidores de tirosina cinasa de bruton.
MX2018004696A (es) Analogos de epotilona, metodos de sintesis, metodos de tratamiento y conjugados con farmacos de los mismos.
MX394038B (es) Derivados de pirrolotriazina como inhibidores de cinasas.

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 APR 2018 BY CPA GLOBAL

Effective date: 20170318

ASS Change of ownership

Owner name: ALKAHEST, INC., US

Effective date: 20170918

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 APR 2019 BY CPA GLOBAL

Effective date: 20180309

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 APR 2020 BY CPA GLOBAL

Effective date: 20190314

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 APR 2021 BY CPA GLOBAL

Effective date: 20200227

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 APR 2022 BY CPA GLOBAL

Effective date: 20210312

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 APR 2023 BY CPA GLOBAL

Effective date: 20220310

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 APR 2024 BY CPA GLOBAL

Effective date: 20230309

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 APR 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20240314

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 APR 2026 BY COMPUTER PACKAGES INC

Effective date: 20250317